TLD-1

liposomal doxorubicin · Swiss Cancer Institute

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for TLD-1, covering 2024-12-02 to 2024-12-02. Get the full timeline:

Most recent: Clinical Trial Update: TLD-1, a Novel Liposomal Doxorubicin, in Patients With Advanced Solid Tumors [Phase 1]